Merck & Co. Inc. raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates. Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor’s office. The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57. The forecast did not include any potential contribution from Merck’s oral COVID-19 drug candidate, molnupiravir. That could give Merck’s profit forecast room to grow if the drug gets U.S. authorization this year. Merck’s shares rose 1 percent before the opening bell. The company earlier this month reported data that showed molnupiravir could halve the …